Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
Eli Lilly CEO David Ricks: Projecting 32% total growth for company in 2025
10:28am, Tuesday, 14'th Jan 2025
Eli Lilly CEO David Ricks joins 'Squawk on the Street' to discuss the company's drug pipeline, 2025 outlook, state of the weight loss drugs market, status of the weight loss drug pill, revised guidanc
Cramer's Mad Dash: Eli Lilly
10:22am, Tuesday, 14'th Jan 2025
CNBC's Jim Cramer delivers his daily Mad Dash.
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
10:20am, Tuesday, 14'th Jan 2025
Eli Lilly cut its 2024 revenue guidance, saying demand for its obesity and diabetes drugs had not met its lofty expectations. Shares dropped about 6%.
Mounjaro and Zepbound sales disappoint, and Eli Lilly's stock is dropping
10:20am, Tuesday, 14'th Jan 2025
Eli Lilly's stock was set to suffer its worst day in four years after sales of diabetes and obesity drugs Mounjaro and Zepbound missed expectations.
Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion Sales From Weight Loss/Diabetes Drugs, Stock Tanks
10:11am, Tuesday, 14'th Jan 2025
On Tuesday, Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, representing a 32% growth compared to the previous year versus
Lilly forecasts weak sales of weight-loss drug in fourth quarter
09:33am, Tuesday, 14'th Jan 2025
Eli Lilly expects sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street expectations in the fourth quarter, but forecast 2025 revenue largely above est
Eli Lilly: 4 Reasons Investors Shouldn't Miss This Opportunity
09:00am, Tuesday, 14'th Jan 2025
Eli Lilly & Co. NYSE: LLY is a major global pharmaceutical company in the medical sector. The company made headlines with its dominant GLP-1 drug, Tirzepatide, sold as Mounjaro for type 2 diabetes and
Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance
09:00am, Tuesday, 14'th Jan 2025
2024 revenue is expected to be approximately $45.0 billion for the full year, $4.0 billion above the midpoint of first-time 2024 financial guidance Q4 2024 revenue is expected to be approximately
Healthcare sector poised for rebound in 2025
08:00pm, Monday, 13'th Jan 2025
The JPMorgan Healthcare Conference is a place where deals happen. As the conference kicked off, deals were announced from Eli Lilly (LLY), Johnson & Johnson (JNJ), and GSK (GSK).
Eli Lilly (LLY) Stock Declines While Market Improves: Some Information for Investors
06:51pm, Monday, 13'th Jan 2025
Eli Lilly (LLY) closed the most recent trading day at $797.48, moving -0.3% from the previous trading session.
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
06:10pm, Monday, 13'th Jan 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil
Eli Lilly CEO on Fighting Cancer and Obesity, Drug Pricing (Correct)
05:54pm, Monday, 13'th Jan 2025
Eli Lilly & Co. Chief Executive Officer Dave Ricks talks about paying $2.5 billion for a cancer drug being developed by Scorpion Therapeutics. He also says Lilly's experimental weight-loss pill coul
Lilly asks US government to pause drug price negotiation program, Bloomberg News reports
01:30pm, Monday, 13'th Jan 2025
Eli Lilly has asked the U.S. government to pause the new law that allows Medicare to negotiate prices for its costliest prescription drugs, Bloomberg News reported on Monday, citing Lilly Chief Execut
Eli Lilly CEO expects new weight loss pill to be approved next year
12:28pm, Monday, 13'th Jan 2025
Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the market with
Drugmakers rush to sign deals on first day of industry conference
12:07pm, Monday, 13'th Jan 2025
Drugmakers signed deals worth at least $18 billion in combined value on Monday, the first day of the healthcare industry's top conference in San Francisco.
